WEE-2005

Regimen

Experimental
Concurrent cisplatin 25 mg/m²/d days 1-4 on weeks 1, 4, 7 + RT 70 Gy, followed by adjuvant cisplatin + 5-FU ×3 cycles
Control
Radiotherapy alone 70 Gy

Population

Locally advanced NPC (all stages), National Cancer Centre Singapore; predominantly ethnic Chinese, non-keratinizing histology

Key finding

Third regional confirmation of CCRT benefit in endemic-area NPC, demonstrating that chemoradiotherapy reduces distant metastasis risk (cumulative incidence difference 17% at 2 years, p=0.0029) in addition to improving locoregional control. Provided the strongest signal for CCRT's impact on distant control among the Asian confirmation trials, reinforcing its inclusion as the backbone for all subsequent induction-chemo addition strategies.

Source: PMID 16170180

Timeline

    Guideline citations

    • NCCN NPC (p.245)